Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Deniz Türkmen has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identifying genetic variants causal for multiple long-term conditions: informing opportunities for intervention and prevention

    by Bethany Voller, Ruby M Woodward, Olivia Murrin, João Delgado, Deniz Türkmen, Rhian Hopkins, Concepción Violán, Mary Mancini, Leon Farmer, Kate Boddy, et al.

    Multiple long-term conditions (MLTC) – the coexistence of two or more long-term conditions (LTCs) in an individual, is an increasingly prevalent and complex clinical challenge. We aimed to uncover opportunities for therapeutic intervention in MLTC and highlight potential adverse effects using genetics to identify shared biological pathways across conditions. Across 72 heritable LTCs common in adults aged ≥65, we analysed genome-wide association study (GWAS) summary statistics from meta-analyses incorporating up to three data sources (UK Biobank, FinnGen, and condition-specific consortia) from genetically European-ancestry participants. Across 843 condition pairs sharing genome-wide significant variants, we performed statistical colocalisation to identify shared causal genetic variants. Variants showing evidence of causality for ≥3 LTCs were prioritised for investigation of likely causal genes, biological pathways, and druggability. Findings were replicated in Our Future Health (OFH, N=550,000). Colocalisation analyses identified 281 genetic variants causal for specific LTC pairs and 85 variants causal for ≥3 LTCs. These 85 variants were located in 34 genomic regions with strong evidence of shared causality across multiple conditions. Thirteen of the 34 regions fully replicated in OFH, with others having partial replication. Eight variants showed concordant directions of effects across conditions, suggesting potential opportunities for drug development; results include a variant in GDF7 causal for diverticular disease, gastro-oesophageal reflux disease, and prostate cancer, suggesting multisystemic mechanisms and a novel intervention target for this cluster of conditions. We identified six potential drug repurposing opportunities involving clinically targeted proteins, including LPA and IRF5 for cardiovascular and immune-mediated inflammatory conditions, respectively. Fifteen variants showed discordant effects across phenotypes, suggesting possible adverse consequences of pharmacological intervention; for example, a variant in GIPR reduced risk of obesity and sleep apnoea whilst increasing risk of breast cancer. These findings reveal shared mechanisms underlying MLTC and highlight opportunities for therapeutic development and repurposing, whilst also identifying possible adverse effects. Author summary: Many individuals live with multiple long-term health conditions, but relatively little is known about the biological processes linking these conditions together. Where conditions share biology, this could reveal new ways to treat diseases. In this study, we used data from large volunteer cohorts of hundreds of thousands of individuals to find regions of DNA associated with multiple conditions. DNA codes for genes, and we found specific genes and biological pathways that partially explain why some conditions occur together. For example, we found evidence linking diverticular disease, gastro-oesophageal reflux disease, and prostate cancer, suggesting that these seemingly different conditions may share underlying biological mechanisms. We identified several proteins that could be explored as new drug targets and opportunities to repurpose existing medications. We also found evidence suggesting that some treatments could have unintended effects, reducing the risk of one condition but increasing the risk of another. This work may help support the development of treatments for people with multiple long-term conditions.

  • Open Access

    Genome-wide association studies identify shared mechanisms between hypertension and type 2 diabetes independent of adiposity

    by Bethany Voller, Ruby M Woodward, Qingze Gu, Olivia Murrin, João Delgado, Concepción Violán, Sara Khalid, Deniz Türkmen, Chris Fox, Sarah E Lamb, et al.

    Background: Hypertension and type 2 diabetes (T2D) are two of the most frequently co-occurring long-term conditions, but their shared mechanisms are not fully understood, often being attributed to adiposity pathways. Here, we aimed to identify shared genetic mechanisms independent of adiposity. Methods: We performed genome-wide association study meta-analyses of T2D and, separately, hypertension. We investigated the bidirectional causal relationship using Mendelian randomisation and quantified genetic correlation before and after accounting for common modifiable risk factors. We then applied a Bayesian GWAS approach to re-estimate SNP-disease effects after accounting for the causal genetic effects of adiposity-related traits. Colocalisation analysis identified shared causal genetic variants, and we investigated the biological pathways involved. Results: We observed a bidirectional causal relationship, and substantial genetic correlation between the two traits (rg = 0.48, 95%CI 0.45-0.52), which persisted after accounting for the genetic contributions of BMI, waist-hip ratio (WHR), and triglycerides (rg = 0.29, 95%CI 0.24-0.34). This indicated shared mechanisms beyond those captured by standard measures of adiposity. We found 98 genetic loci containing variants significantly associated with both hypertension and T2D; colocalisation analysis identified 37 that contained specific shared causal variants. Of these, eight remained statistically significant after adjusting for genetic measures of adiposity, and four were identified only after removing the causal effect of adiposity measures. Shared variants include an allele within PCSK7 associated with risk of both T2D and hypertension and with circulating PCSK7 protein levels, as well as a variant in the 3′ untranslated region of ZNF101, within the TM6SF2 locus, likely reflecting regulatory variation affecting hepatic lipid metabolism and cardiometabolic traits. Conclusions: We identify shared causal mechanisms between hypertension and T2D independent of several measures of adiposity. These findings, particularly PCSK7, could uncover novel interventions or opportunities for prevention of this co-occurring condition pair.


  • Open Access

    Understanding the causes and consequences of low statin adherence: evidence from UK Biobank primary care data

    by Deniz Türkmen, Xiaoran Liang, Jane A H Masoli, Dipender Gill, Luke C Pilling, Jack Bowden

    Background: Statins are commonly prescribed to lower LDL cholesterol. Clinical guidelines recommend 30-50% reduction within 3 months, yet many patients do not achieve this. We investigated the impact of patient characteristics and genetics on LDL-c reduction, treatment adherence, and adverse clinical outcomes. Methods: We analysed 76,000 UK Biobank participants prescribed atorvastatin or simvastatin in primary care: 41,000 had LDL-c measurements before statin initiation (median=16 days prior, IQR=28) and within a year of starting treatment (median=89 days, IQR=125). Adherence was defined as the “proportion of days covered” (PDC). We estimated associations between PDC within one year of statin initiation, genetic factors, post-treatment LDL reduction, and clinical adverse outcomes. For 13,000 patients with ≥3 LDL-c measures, we used inverse probability weighting methods to estimate the effect of sustained adherence intervention on LDL-c reduction longitudinally. Results: Predictors of LDL-c reduction following statin initiation included the time until the 1 st measurement, PDC, and the pharmacogenetic variant SLCO1B1 *5. LDL-c reduction was greater in those with high adherence versus lower adherence (38% reduction when PDC>95% [high] vs. 15% when PDCtop 20% -1.94, 95%CI -2.69 to -1.19), whilst genetic liability to cardiovascular diseases increased PDC (Coef top 20% 1.30, 95%CI 0.55 to 2.05). High PDC was associated with increased risk of incident iron deficiency anaemia (HR 1.30, 95%CI 1.09-1.54) and cataract (HR 1.20, 95%CI 1.07-1.34), and decreased risk of incident coronary heart disease (HR 0.78, 95%CI 0.73-0.84). Conclusion: We identify substantial variability in the time to first on-treatment LDL measurements and also in adherence to statin medication, highlighting a gap between NHS guidelines, LDL monitoring and statin adherence. We show its subsequent impact on long term health, demonstrating the potential effect of targeted interventions to improve adherence. We identify important predictors of reduced statin effectiveness, including pharmacogenetic variants, polygenic scores, but most of all, adherence. Tailored statin therapy strategies with patient education on statin indication and adherence could optimise treatment efficacy, safety, and long-term clinical outcomes.

  • Open Access

    Polygenic scores for cardiovascular risk factors improve estimation of clinical outcomes in CCB treatment compared to pharmacogenetic variants alone

    by Deniz Türkmen, Jack Bowden, Jane A. H. Masoli, João Delgado, Chia-Ling Kuo, David Melzer, Luke C. Pilling

    Pharmacogenetic variants are associated with clinical outcomes during Calcium Channel Blocker (CCB) treatment, yet whether the effects are modified by genetically predicted clinical risk factors is unknown. We analyzed 32,000 UK Biobank participants treated with dihydropiridine CCBs (mean 5.9 years), including 23 pharmacogenetic variants, and calculated polygenic scores for systolic and diastolic blood pressures, body fat mass, and other patient characteristics. Outcomes included treatment discontinuation and heart failure. Pharmacogenetic variant rs10898815-A (NUMA1) increased discontinuation rates, highest in those with high polygenic scores for fat mass. The RYR3 variant rs877087 T-allele alone modestly increased heart failure risks versus non-carriers (HR:1.13, p = 0.02); in patients with high polygenic scores for fat mass, lean mass, and lipoprotein A, risks were substantially elevated (HR:1.55, p = 4 × 10−5). Incorporating polygenic scores for adiposity and lipoprotein A may improve risk estimates of key clinical outcomes in CCB treatment such as treatment discontinuation and heart failure, compared to pharmacogenetic variants alone.


  • Open Access

    SLCO1B1 Exome Sequencing and Statin Treatment Response in 64,000 UK Biobank Patients

    by Deniz Türkmen, Jack Bowden, Jane A. H. Masoli, David Melzer, Luke C. Pilling

    The solute carrier organic anion transporter family member 1B1 (SLCO1B1) encodes the organic anion-transporting polypeptide 1B1 (OATP1B1 protein) that transports statins to liver cells. Common genetic variants in SLCO1B1, such as *5, cause altered systemic exposure to statins and therefore affect statin outcomes, with potential pharmacogenetic applications; yet, evidence is inconclusive. We studied common and rare SLCO1B1 variants in up to 64,000 patients from UK Biobank prescribed simvastatin or atorvastatin, combining whole-exome sequencing data with up to 25-year routine clinical records. We studied 51 predicted gain/loss-of-function variants affecting OATP1B1. Both SLCO1B1*5 alone and the SLCO1B1*15 haplotype increased LDL during treatment (beta*5 = 0.08 mmol/L, p = 6 × 10−8; beta*15 = 0.03 mmol/L, p = 3 × 10−4), as did the likelihood of discontinuing statin prescriptions (hazard ratio*5 = 1.12, p = 0.04; HR*15 = 1.05, p = 0.04). SLCO1B1*15 and SLCO1B1*20 increased the risk of General Practice (GP)-diagnosed muscle symptoms (HR*15 = 1.22, p = 0.003; HR*20 = 1.25, p = 0.01). We estimated that genotype-guided prescribing could potentially prevent 18% and 10% of GP-diagnosed muscle symptoms experienced by statin patients, with *15 and *20, respectively. The remaining common variants were not individually significant. Rare variants in SLCO1B1 increased LDL in statin users by up to 1.05 mmol/L, but replication is needed. We conclude that genotype-guided treatment could reduce GP-diagnosed muscle symptoms in statin patients; incorporating further SLCO1B1 variants into clinical prediction scores could improve LDL control and decrease adverse events, including discontinuation.


  • Open Access

    Combining pharmacogenetics and patient characteristic polygenic scores to improve outcome prediction for Calcium Channel Blocker treatment

    by Deniz Türkmen, Jack Bowden, Jane A.H. Masoli, João Delgado, Chia-Ling Kuo, Luke C. Pilling, David Melzer

    Background: Calcium channel blockers (CCBs) are common antihypertensive medications. Pharmacogenetic variants affect CCB clinical outcomes, although effect sizes are modest in community samples. Variation in patient characteristics may also predict CCB outcomes, and variation attributable to relevant polygenic scores is less prone to confounding. We aimed to test associations between genetically predicted patient characteristics plus pharmacogenetic variants with CCB outcomes in a large community cohort. Methods: We extended our analysis of 32,000 UK Biobank dihydropiridine CCBs treated participants (mean duration 5.9 years) testing 23 variants, where NUMA1 rs10898815 and RYR3 rs877087 showed the most robust associations (for discontinuation and heart failure, respectively). We calculated polygenic scores for systolic and diastolic blood pressures (SBP and DBP), body fat mass, waist hip ratio, lean mass, serum calcium, eGFR, lipoprotein A, urinary sodium, and liver fibrosis. Outcomes were CCB discontinuation, heart failure, coronary heart disease and chronic kidney disease. Results: For heart failure, the highest risk 20% of polygenic scores for fat mass, lean mass and lipoprotein A were associated with increased risks (Hazard-Ratio (HR)Fat-mass 1.46, 95% CI 1.25-1.70, p=1*10-6; HRLean-mass 1.20, 95%CI 1.04-1.38, p=0.01; HRLipoproteinA 1.29, 95% CI 1.12 to 1.48, p= 4*10-4), versus the lowest risk 20% of each score respectively. Across the cohort, RYR3 T-allele modestly increased heart failure risks (HR 1.13: 1.02-1.25) versus non-carriers, but in subsets with high fat mass, lean mass, and lipoprotein A scores, estimates were substantially larger, e.g., in females aged 65-70 the heart failure Relative Risk was 4.4 (95% CI 1.54-12.4) versus no T-alleles and low scores. For CCB discontinuation, high polygenic scores for fat mass and lean mass increased risks versus the lowest 20%, whereas high SBP and DBP scores decreased discontinuation risks. Hazard ratios for discontinuation with the pharmacogenetic NUMA1 rs10898815 A-allele (overall HR 1.07: 1.02-1.12) were higher (HR 1.17: 1.05-1.29) in those with high polygenic scores for fat mass and lean mass. Conclusion: Polygenic scores affecting adiposity and lipoprotein A levels add to known pharmacogenetic variants in predicting key clinical outcomes in CCB treatment. Combining pharmacogenetic variants and relevant individual characteristic polygenic scores may help for personalizing prescribing. What is needed, what do we add?: We previously showed that pharmacogenetic variants in RYR3 and NUMA1 were associated with key clinical outcomes in community CCB patients, although effect sizes were modest. Various patient characteristics reportedly affect CCB outcomes. We therefore tested effects of relevant patient characteristics using polygenic scores. They minimize the effect of unmeasured confounders as genotypes are invariant since conception and reflect lifetime exposure to the risk factor. We showed that combining associated scores with the pharmacogenetic variants improved outcome prediction.

  • Open Access

    Calcium‐channel blockers: Clinical outcome associations with reported pharmacogenetics variants in 32 000 patients

    by Deniz Türkmen, Jane A. H. Masoli, João Delgado, Chia‐Ling Kuo, Jack Bowden, David Melzer, Luke C. Pilling

    Aims: Pharmacogenetic variants impact dihydropyridine calcium‐channel blockers (dCCBs; e.g., amlodipine) treatment efficacy, yet evidence on clinical outcomes in routine primary care is limited. Reported associations in pharmacogenomics knowledge base PharmGKB have weak supporting evidence. We aimed to estimate associations between reported pharmacogenetic variants and incident adverse events in a community‐based cohort prescribed dCCB.Methods: We analysed up to 32 360 UK Biobank participants prescribed dCCB in primary care (from UK general practices, 1990–2017). We investigated 23 genetic variants. Outcomes were incident diagnosis of coronary heart disease, heart failure (HF), chronic kidney disease, oedema and switching antihypertensive medication.Results: Participants were aged 40–79 years at first dCCB prescription. Carriers of rs877087 T allele in RYR3 had increased risk of hazard ratio (HF 1.13: 95% confidence interval 1.02 to 1.25, P = .02). Although nonsignificant after multiple testing correction, the association is consistent with prior evidence. We estimated that if rs877087 T allele could experience the same treatment effect as noncarriers, the incidence of HF in patients prescribed dCCB would reduce by 9.2% (95% confidence interval 3.1 to 15.4). In patients with a history of heart disease prior to dCCB (n = 2296), rs877087 homozygotes had increased risk of new coronary heart disease or HF compared to CC variant. rs10898815 in NUMA1 and rs776746 in CYP3A5 increased likelihood of switching to an alternative antihypertensive. The remaining variants were not strongly or consistently associated with studied outcomes.Conclusion: Patients with common genetic variants in NUMA1, CYP3A5 and RYR3 had increased adverse clinical outcomes. Work is needed to establish whether outcomes of dCCB prescribing could be improved by prior knowledge of pharmacogenetics variants supported by clinical evidence of association with adverse events.


  • Open Access

    Calcium Channel Blockers: clinical outcome associations with reported pharmacogenetics variants in 32,000 patients

    by Deniz Türkmen, Jane A.H. Masoli, João Delgado, Chia-Ling Kuo, Jack Bowden, David Melzer, Luke C. Pilling

    Background: Dihydropiridine calcium channel blockers (dCCB) (e.g. amlodipine) are widely used for treating hypertension. Pharmacogenetic variants impact treatment efficacy, yet evidence on clinical outcomes in routine primary care is limited. We aimed to estimate associations between reported pharmacogenetic variants and incident adverse events in a community-based cohort prescribed dCCB, including in high-risk subgroups. Methods: We analysed up to 32,360 UK Biobank European-ancestry participants prescribed dCCB in primary care electronic health records (from UK General Practices, 1990 to 2017). We investigated 23 genetic variants in 16 genes reported in PharmGKB, including CYP3A5 and RYR3 . Outcomes were incident diagnosis of coronary heart disease (CHD), heart failure (HF), chronic kidney disease (CKD), edema, and switching antihypertensive medication. Secondary analysis in patients with history of heart disease was also performed. Results: Participants were aged 40 to 79 years at first dihydropyridine prescription (treatment duration 1 month to 40 years, mean 5.9 years). Carriers of rs877087 T allele in the ryanodine receptor 3 ( RYR3 ) had increased risk of HF (Hazard Ratio 1.13: 95% Confidence Intervals 1.02 to 1.25, p=0.02). We estimated that if rs877087 T allele carriers were prescribed an alternative treatment the incidence of HF in patients prescribed dCCB would reduce by 9.2% (95%CI 3.1 to 15.4). In patients with a history of heart disease when first prescribed dCCB (N=2,296), RYR3 rs877087 homozygotes had increased risk of new CHD or HF compared to CC variant (HR 1.25, 95%CI 1.09 to 1.44, p =0.002). Two variants increased likelihood of switching to an alternate antihypertensive medication (rs10898815 in gene NUMA1 HR 1.16: 95%CI 1.07 to 1,27, p=0.0009; rs776746 in CYP3A5 HR 1.59: 95%CI 1.09 to 2.32, p=0.02). rs776746 in CYP3A5 also increased CKD risk (HR 2.12, p=0.002). The remaining previously reported variants were not strongly or consistently associated with the studied clinical outcomes. Conclusions: In this large primary care cohort, patients with common genetic variants in NUMA1, CYP3A5 and RYR3 had increased adverse clinical outcomes. Work is needed to establish whether outcomes of dCCB prescribing could be improved by prior knowledge of such pharmacogenetics variants supported by clinical evidence of association with adverse events.


  • Open Access

    Statin treatment effectiveness and the SLCO1B1*5 reduced function genotype: Long‐term outcomes in women and men

    by Deniz Türkmen, Jane A. H. Masoli, Chia‐Ling Kuo, Jack Bowden, David Melzer, Luke C. Pilling

    Objective: To estimate the effect of rs4149056 (SLCO1B1*5) genotype (decreases statin transport) on cholesterol control and treatment duration in male and female primary care patients prescribed common statin medications.Methods and Analysis: This study comprised 69 185 European‐ancestry UK Biobank cohort participants prescribed simvastatin or atorvastatin (aged 40‐79 years at first prescription, treatment duration 1 month to 29 years, mean 5.7 years). Principal outcomes were clinically high total cholesterol (>5 mmol/L) at baseline, plus treatment discontinuation.Results: A total of 48.4% of 591 females homozygous for SLCO1B1*5 decreased function genotype had raised cholesterol vs 41.7% of those with functioning SLCO1B1 (odds ratio 1.31, 95% confidence interval [CI] 1.1‐1.55, P = .001). Fewer males had high cholesterol and the genotype effect was attenuated. In primary care prescribing, females homozygous for SLCO1B1*5 were more likely to stop receiving these statins (29.5%) than women with normal SLCO1B1 (25.7%) (hazard ratio [HR] 1.19, 95% CI 1.03‐1.37, P = .01), amounting to five discontinuations per 100 statin‐years in the SLCO1B1*5 group vs four in the normal SLCO1B1 function group. This remained significant after the first year of treatment (HR for discontinuing >1 year after first prescription 1.3, 95% CI 1.08‐1.56, P = .006). In men SLCO1B1*5 was only associated with treatment discontinuation in the first year.Conclusions: In this large community sample of patients on commonly prescribed statins, the SLCO1B1*5 decreased function variant had much larger effects on cholesterol control and treatment duration in women than in men. Efforts to improve the effectiveness of statin therapy in women may need to include SLCO1B1*5 genotype‐guided statin selection.


  • Open Access

    Analysis of CYP2C19 genetic variants with ischaemic events in UK patients prescribed clopidogrel in primary care: a retrospective cohort study

    by Luke C Pilling, Deniz Türkmen, Hannah Fullalove, Janice L Atkins, Joao Delgado, Chia-Ling Kuo, George A Kuchel, Luigi Ferrucci, Jack Bowden, Jane A H Masoli, et al.

    Objective: To determine whether CYP2C19 loss-of-function (LoF) alleles increase risk of ischaemic stroke and myocardial infarction (MI) in UK primary care patients prescribed clopidogrel. Design: Retrospective cohort analysis. Setting: Primary care practices in the UK from January 1999 to September 2017. Participants: 7483 European-ancestry adults from the UK Biobank study with genetic and linked primary care data, aged 36–79 years at time of first clopidogrel prescription. Interventions: Clopidogrel prescription in primary care, mean duration 2.6 years (range 2 months to 18 years). Main outcome measure: Hospital inpatient-diagnosed ischaemic stroke, MI or angina while treated with clopidogrel. Results: 28.7% of participants carried at least one C YP2C19 LoF variant. LoF carriers had higher rates of incident ischaemic stroke while treated with clopidogrel compared with those without the variants (8 per 1000 person-years vs 5.2 per 1000 person-years; HR 1.53, 95% CIs 1.04 to 2.26, p=0.031). LoF carriers also had increased risk of MI (HR 1.14, 95% CI 1.04 to 1.26, p=0.008). In combined analysis LoF carriers had increased risk of any ischaemic event (stroke or MI) (HR 1.17, 95% CI 1.06 to 1.29, p=0.002). Adjustment for aspirin coprescription produced similar estimates. In lifetables using observed incidence rates, 22.5% (95% CI 14.4% to 34.0%) of CYP2C19 LoF carriers on clopidogrel were projected to develop an ischaemic stroke by age 79 (oldest age in the study), compared with 15.4% (95% CI 11.4% to 20.5%) in non-carriers, that is, 7.1% excess stroke incidence in LoF carriers by age 79. Conclusions: A substantial proportion of the UK population carry genetic variants that reduce metabolism of clopidogrel to its active form. In family practice patients on clopidogrel, CYP2C19 LoF variants are associated with substantially higher incidence of ischaemic events. Genotype-guided selection of antiplatelet medications may improve outcomes in patients carrying CYP2C19 genetic variants.